- 1、本文档共24页,可阅读全部内容。
- 2、原创力文档(book118)网站文档一经付费(服务费),不意味着购买了该文档的版权,仅供个人/单位学习、研究之用,不得用于商业用途,未经授权,严禁复制、发行、汇编、翻译或者网络传播等,侵权必究。
- 3、本站所有内容均由合作方或网友上传,本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺!文档内容仅供研究参考,付费前请自行鉴别。如您付费,意味着您自己接受本站规则且自行承担风险,本站不退款、不进行额外附加服务;查看《如何避免下载的几个坑》。如果您已付费下载过本站文档,您可以点击 这里二次下载。
- 4、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等,请点击“版权申诉”(推荐),也可以打举报电话:400-050-0827(电话支持时间:9:00-18:30)。
查看更多
第 1 页 共 14 页
2021 年 6 月大学英语六级仔细阅读练习题附答案及解析 (3)
Passage One
Questions 56 to 60 are based on the following passage.
Caught in a squeeze between the health needs of aging populations on one hand and the financial crisis on the other, governments everywhere are looking for ways to slow the growth in health-care spending. Increasingly, they are looking to the generic-drugs (普通药物 ) industry as a savior. In November Japans finance ministry issued a report complaining that the countrys use of generics was less than a third of that in America or Britain. In the same month Canadas competition watchdog criticized the countrys pharmacies for failing to pass on the savings made possible by the useof generic drugs. That greed, it reckoned, costs taxpayers nearly C$1 billion a year.
Then on November 28th the European Commission issued the preliminary results of its year-long probe into drug giants in the European Union. The report reached a damning~, though provisional, conclusion: the drugs firms use a variety of unfair strategies to protect their expensive drugs by delaying
第 2 页 共 14 页
the entry of cheaper generic opponents. Though this initial report does not carry the force of law (a final report is due early next year), it has caused much controversy. Neelie Kroes, the EUs competition commissioner, says she is ready to take legal action if the evidence allows.
One strategy the investigators criticize is the use of the patent duster( 专利群). A firm keen to defend its drug due to go off-patent may file dozens or hundreds of new patents, often of dubious merit, to confuse and terrify potential copycats and maintain its monopoly. An unnamed drugs firm once took out 1,300 patents across the EU on a single drug. The report also suggests that out-of-court settlements between makers of patented drags and generics firms may be a strategy used by the former to delay market entry by the latter.
According to EU officials, such misdeeds -have delayed the arrival of generic compe
文档评论(0)